In recent years, those applying computer science to biology have had no trouble raising the money to take their innovations straight into the commercial world. The promise was simple: get

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost

Biopharmaceutical company Poolbeg has selected as strategic priority a number of potential treatments for Respiratory Syncytial Virus. The drug targets were selected from a list identified as part of Poolbeg’s

Poolbeg Pharma says it has successfully used artificial intelligence to identify drug targets for the treatment of Respiratory Syncytial Virus (RSV). The programme identified the RSV drug treatment candidates in

In the past year, generative artificial intelligence (GAI) has emerged as a potentially groundbreaking force in the pharmaceutical industry. This technology, which involves AI systems that can generate novel data

Advances in AI promise to transform drug discovery and development. AI not only brings more efficiency to today’s costly and slow processes but also holds the potential to identify entirely

Poolbeg Pharma, the Dublin-headquartered biopharmaceutical company, could reach a €1 billion valuation, according to Jeremy Skillington, its chief executive. Skillington compared the potential of Poolbeg to that of Amryt Pharma,

Background Cytokine Release Syndrome (CRS) is a well-recognized toxicity that occurs with high frequency following treatments such as T-cell engaging antibodies, Chimeric Antigen Receptor (CAR) T cells and other T-cell